Skip to main content
Quest Diagnostics
Call
Menu

Quest Diagnostics is bringing a new perspective to this year's American Academy of Neurology (AAN) Annual Meeting. Stop by booth #4030, or sign up for time with our team using the link below to discover how our solutions provide clarity, confidence, and continuity across the neurology care spectrum.

Let's meet at AAN

  • Engage directly with our medical, scientific, and commercial teams
  • Learn how the blood-based biomarker test from Quest Diagnostics can support your patients throughout the Alzheimer's and dementia care pathway, reducing costly and invasive testing
  • Explore how Quest Diagnostics streamlines its broad menu of over 400 neurology tests and provides expert insights to provide clarity amid complex conditions
Connect with our team at AAN

Aligning diagnostics to every protocol and patient path

Through a testing portfolio that unites science, insight, and action, Quest provides a trusted path from discovery to care, ensuring progress remains connected and continually moves you, your patients, and the neurology field forward.

KNOWING WHERE TO LOOK FIRST

Neuroimmunology

Quest Advanced Neurology is your source for neuroimmunological testing with expanded offerings for several autoimmune neurological disorders, such as

  • Multiple Sclerosis (MS) Differential Evaluation with Reflexes
  • Pediatric Autoimmune Encephalitis Evaluation with Reflexes
Learn more
AD-Detect HCP Brochure Image

HELPING TO TURN UNCERTAINTY INTO ANSWERS

Whole-exome sequencing (WES)

Whole-exome sequencing (WES) assists with diagnosing genetic conditions in situations when targeted genetic testing was unsuccessful.
 
Quest Diagnostics uses a rules-based, weighted process (published by Quest researchers in 2015) that is aligned with the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) guidelines. We also follow American Academy of Pediatrics (AAP) recommendations for WES and Whole-Genome Sequencing (WGS)­—including using these as first-tier tests for children with certain developmental delays.

 

 

Learn more
sales rep speaking with doctor

EXPAND YOUR APPROACH TO ASSESSMENT

AD-Detect® ABeta 42/40 and p-tau217 Evaluation with AD-Detect Likelihood Score

When paired with clinical cognitive testing, our AD-Detect® ABeta 42/40 and

p-tau217 Evaluation can help uncover a broader view of what may be contributing to your patient's cognitive impairment. And the sooner you have that information, the sooner you and your patients can take actions like make more informed referrals so that specialists are ready to take the best next step in patient care.

 

 

Learn more
Female doctor talking with senior man in waiting room

Scientific contributions at this year's AAN

We're advancing the conversation in neurological disorder assessment through new research. Explore our scientific contributions presented at AAN, showcasing findings that help providers deliver more effective, comprehensive brain healthcare.

Presentation

Real world use of plasma beta amyloid 42/40 and Ptau-217 in a national laboratory

Presenter: Michael K Racke, MD, Medical Director, Neurology, Quest Diagnostics

Wednesday, April 22, 8:00 AM CST

Read the abstract

New scientific publication

Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer's disease pathology

Li Y, Lagier RJ, Racke MK, Fesko YA. J Prev Alzheimers Dis. 2026 ;13(3):100474. Epub January 14, 2026. doi: 10.1016/j.tjpad.2025.100474

Read the article
Connect with our team at AAN

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.